For over a century, horses have played a vital role in the production of antivenom, a life-saving treatment for snakebites. Each year, between 80,000 and 140,000 people die from snakebites globally, with many more suffering from amputations or long-term disabilities. In India, where nearly half of these deaths occur, around 58,000 people lose their lives annually to snakebites. Most victims are rural residents—farmers, laborers, and children—who are bitten while working in the fields or walking home at night. Traditional antivenom is made by injecting horses with small amounts of snake venom, which triggers their immune systems to produce antibodies. These antibodies are then harvested and processed into antivenom. While this method has saved many lives, it has several limitations. It can vary in quality between batches, may cause severe allergic reactions in some people, is expensive to produce, and often doesn’t work well against venoms from different snake species or even different populations of the same species. In India, antivenom is typically made using venoms from four major snake species known as the "big four": the Indian spectacled cobra, common krait, Russell’s viper, and saw-scaled viper. However, these antivenoms are not always effective against venoms from other snake species or even variations of the same species found in different regions. This has led researchers to explore more modern approaches to snakebite treatment. A recent study in mice suggests that nanobodies, which are small, specialized versions of antibodies, could offer a more effective alternative. These nanobodies can move quickly through the body, reaching snake venom before it causes irreversible damage. Unlike traditional antivenom, they can be produced using microbes, rather than horses. Researchers have already developed nanobodies that neutralize venoms from African cobras and mambas. When tested against venoms from several cobra and king cobra species in India, five different nanobodies were able to target toxins from multiple venom types. This was promising, as the nanobodies had originally been developed using venoms from African snakes. In experiments with mice, the nanobody cocktail was highly effective when given alongside venom, with all treated mice surviving. Untreated mice, on the other hand, died within 30 minutes due to neurotoxic effects. The treatment was also effective when administered 20 minutes after venom exposure, preventing severe symptoms like paralysis and breathing failure. Researchers confirmed that the nanobodies did not bind to human proteins, which is critical to avoid side effects, and that they remained stable at high temperatures—an important feature for regions without reliable cold storage for medicines. While the results are encouraging, the study was conducted in mice, and further research is needed to confirm its effectiveness in humans. The current treatment is not a universal antivenom and does not work against Indian kraits, meaning additional nanobodies would be required to target these and other dangerous snakes. More studies are needed to determine the correct dosage, how long the treatment remains effective, and how it performs when delayed in larger animals and humans. The next step is to test the antivenom in humans, ensuring its safety and proper dosage, and producing it to pharmaceutical standards. Once approved, it could be used in hospitals for people bitten by snakes. These findings suggest that nanobody-based antivenoms could provide a more adaptable and effective approach to treating snakebites. Instead of creating a new treatment for each snake species, a shared set of nanobodies could be combined and adapted for different regions, potentially saving many lives each year.